Horrell Capital Management Inc. lessened its holdings in GW Pharmaceuticals PLC- (NASDAQ:GWPH) by 25.0% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 300 shares of the biopharmaceutical company’s stock after selling 100 shares during the period. Horrell Capital Management Inc.’s holdings in GW Pharmaceuticals PLC- were worth $31,000 at the end of the most recent quarter.
A number of other large investors have also bought and sold shares of the stock. Massachusetts Financial Services Co. MA lifted its position in shares of GW Pharmaceuticals PLC- by 28.6% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 101,194 shares of the biopharmaceutical company’s stock worth $11,640,000 after buying an additional 22,481 shares during the period. Penserra Capital Management LLC bought a new position in GW Pharmaceuticals PLC- in the 3rd quarter valued at $270,000. Virtu Financial LLC raised its position in GW Pharmaceuticals PLC- by 99.3% in the 3rd quarter. Virtu Financial LLC now owns 3,838 shares of the biopharmaceutical company’s stock valued at $441,000 after purchasing an additional 1,912 shares during the last quarter. Nomura Holdings Inc. acquired a new position in GW Pharmaceuticals PLC- in the third quarter worth $5,005,000. Finally, Usca Ria LLC grew its holdings in shares of GW Pharmaceuticals PLC- by 17.3% during the third quarter. Usca Ria LLC now owns 2,112 shares of the biopharmaceutical company’s stock worth $243,000 after purchasing an additional 312 shares during the last quarter. 81.09% of the stock is owned by hedge funds and other institutional investors.
GWPH has been the subject of a number of research analyst reports. BidaskClub raised GW Pharmaceuticals PLC- from a “sell” rating to a “hold” rating in a report on Tuesday. Evercore ISI reissued a “buy” rating on shares of GW Pharmaceuticals PLC- in a report on Monday, November 11th. Needham & Company LLC assumed coverage on shares of GW Pharmaceuticals PLC- in a research report on Monday, October 21st. They issued a “buy” rating and a $200.00 price objective for the company. Zacks Investment Research downgraded GW Pharmaceuticals PLC- from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Finally, Oppenheimer decreased their price objective on GW Pharmaceuticals PLC- to $222.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. Three equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $191.82.
In related news, Chairman Geoffrey W. Dr Guy sold 420,000 shares of the business’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $108.41, for a total value of $45,532,200.00. Also, Director Cabot Brown sold 3,576 shares of the business’s stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $8.58, for a total transaction of $30,682.08. Following the completion of the sale, the director now directly owns 20,232 shares in the company, valued at $173,590.56. The disclosure for this sale can be found here. Insiders sold a total of 428,916 shares of company stock worth $45,611,850 over the last ninety days. 3.60% of the stock is currently owned by insiders.
Shares of NASDAQ:GWPH traded up $1.02 during midday trading on Tuesday, reaching $118.13. 529,823 shares of the company were exchanged, compared to its average volume of 438,025. The firm has a market cap of $3.32 billion, a PE ratio of -11.19 and a beta of 2.13. GW Pharmaceuticals PLC- has a fifty-two week low of $95.71 and a fifty-two week high of $196.00. The stock has a fifty day simple moving average of $103.91 and a two-hundred day simple moving average of $131.25. The company has a quick ratio of 6.60, a current ratio of 7.33 and a debt-to-equity ratio of 0.03.
GW Pharmaceuticals PLC- (NASDAQ:GWPH) last posted its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.39. The business had revenue of $90.97 million for the quarter, compared to analysts’ expectations of $86.84 million. GW Pharmaceuticals PLC- had a negative net margin of 26.80% and a negative return on equity of 23.04%. As a group, analysts forecast that GW Pharmaceuticals PLC- will post -3.5 earnings per share for the current year.
About GW Pharmaceuticals PLC-
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.
See Also: Closed-End Mutual Funds
Want to see what other hedge funds are holding GWPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GW Pharmaceuticals PLC- (NASDAQ:GWPH).
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.